Lenz Ther­a­peu­tics eyes bet­ter vi­sion than Ab­b­Vie, Ora­sis with $80M+ for three PhI­II tri­als

Lenz Ther­a­peu­tics thinks it can de­liv­er a bet­ter eye drop than Ab­b­Vie’s Vuity and Ora­sis Phar­ma­ceu­ti­cals’ CSF-1, un­der FDA re­view. And the San Diego biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER